{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:54:08Z","timestamp":1791338048555,"version":"4.3.1"},"reference-count":38,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3,1]]},"abstract":"<jats:p>Background: Several interferon beta (IFN\u03b2) formulations are approved for first-line use as disease-modifying therapies to treat patients with multiple sclerosis (MS). Systemic post-injection reactions, often termed flu-like symptoms (FLS), occur in approximately half of all patients treated with IFN\u03b2s and can affect adherence to therapy. These symptoms, which include pyrexia, chills, malaise, myalgia, and headaches, usually resolve within 24 hours or persist intermittently following each injection. Because FLS, which usually occur early in the treatment course and diminish over time, are a primary cause of nonadherence to IFN\u03b2 therapy, it is important to employ strategies that can attenuate these side effects.<\/jats:p>\n               <jats:p>Methods: To identify interventions effective in limiting FLS, a panel of United States\u2013based nurses with expertise in MS patient care was convened and a literature review completed.<\/jats:p>\n               <jats:p>Results: Panel consensus was reached on specific interventions that can attenuate FLS. These prevention and mitigation strategies include dose titration, analgesia, and optimal injection timing, as well as other techniques that panel members have found useful in their clinical practice experience.<\/jats:p>\n               <jats:p>Conclusions: These measures, in addition to effective patient education, will help to reduce the incidence of FLS secondary to IFN\u03b2 therapy, improve patient medication adherence, and positively affect long-term clinical outcomes.<\/jats:p>","DOI":"10.7224\/1537-2073.2013-006","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T10:17:45Z","timestamp":1395915465000},"page":"55-60","source":"Crossref","is-referenced-by-count":20,"title":["Nurses\u2019 Perspective on Approaches to Limit Flu-Like Symptoms During Interferon Therapy for Multiple Sclerosis"],"prefix":"10.7224","volume":"16","author":[{"given":"Mary L.","family":"Filipi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Beavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel T.","family":"Brillante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail C.","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Namey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"O'Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Remington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4242","reference":[{"key":"2020071713460878900_i1537-2073-16-1-55-b1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","article-title":"Multiple sclerosis","volume":"359","author":"Compston","year":"2002","journal-title":"Lancet"},{"key":"2020071713460878900_i1537-2073-16-1-55-b2","article-title":"Multiple sclerosis: hope through research: treatments to help reduce disease activity and progression","author":"National Institute of Neurological Disorders and Stroke"},{"key":"2020071713460878900_i1537-2073-16-1-55-b3","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/01.wnl.0000200778.65597.ae","article-title":"IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event","volume":"66","author":"Kinkel","year":"2006","journal-title":"Neurology"},{"key":"2020071713460878900_i1537-2073-16-1-55-b4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(09)70237-6","article-title":"Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial","volume":"8","author":"Kappos","year":"2009","journal-title":"Lancet Neurol"},{"issue":"suppl 1","key":"2020071713460878900_i1537-2073-16-1-55-b5","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1212\/WNL.0b013e318205051d","article-title":"Long-term follow-up of clinical trials of multiple sclerosis therapies","volume":"76","author":"Freedman","year":"2011","journal-title":"Neurology"},{"key":"2020071713460878900_i1537-2073-16-1-55-b6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"2020071713460878900_i1537-2073-16-1-55-b7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/1352458506070446","article-title":"Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy","volume":"13","author":"Zivadinov","year":"2007","journal-title":"Mult Scler"},{"key":"2020071713460878900_i1537-2073-16-1-55-b8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-beta in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drugs"},{"key":"2020071713460878900_i1537-2073-16-1-55-b9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1517\/13543784.12.4.689","article-title":"Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies","volume":"12","author":"Wiendl","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"2020071713460878900_i1537-2073-16-1-55-b10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00023210-200519030-00005","article-title":"US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles","volume":"19","author":"Galetta","year":"2005","journal-title":"CNS Drugs"},{"key":"2020071713460878900_i1537-2073-16-1-55-b11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10072-003-0190-3","article-title":"Long-term interferon-beta treatment for multiple sclerosis","volume":"24","author":"Ruggieri","year":"2003","journal-title":"Neurol Sci"},{"key":"2020071713460878900_i1537-2073-16-1-55-b12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11533330-000000000-00000","article-title":"Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study","volume":"30","author":"Steinberg","year":"2010","journal-title":"Clin Drug Investig"},{"key":"2020071713460878900_i1537-2073-16-1-55-b13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","article-title":"Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis","volume":"28","author":"Tan","year":"2011","journal-title":"Adv Ther"},{"key":"2020071713460878900_i1537-2073-16-1-55-b14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1468-1331.2010.03110.x","article-title":"The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis","volume":"18","author":"Devonshire","year":"2011","journal-title":"Eur J Neurol"},{"key":"2020071713460878900_i1537-2073-16-1-55-b15","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/1352458511433302","article-title":"Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence","volume":"18","author":"Giovannoni","year":"2012","journal-title":"Mult Scler"},{"key":"2020071713460878900_i1537-2073-16-1-55-b16","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1185\/030079907X210741","article-title":"Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study","volume":"23","author":"Brandes","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"2020071713460878900_i1537-2073-16-1-55-b17","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1185\/03007990802329959","article-title":"Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis","volume":"24","author":"Moses","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2020071713460878900_i1537-2073-16-1-55-b18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00041327-200112000-00013","article-title":"The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study)","volume":"21","author":"Galetta","year":"2001","journal-title":"J Neuroophthalmol"},{"key":"2020071713460878900_i1537-2073-16-1-55-b19","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1185\/03007995.2011.630720","article-title":"Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation","volume":"27","author":"Matson","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"2020071713460878900_i1537-2073-16-1-55-b20","article-title":"Betaseron [package insert]","year":"2010"},{"key":"2020071713460878900_i1537-2073-16-1-55-b21","article-title":"Avonex [package insert]","year":"2011"},{"key":"2020071713460878900_i1537-2073-16-1-55-b22","article-title":"Rebif [package insert]","year":"2009"},{"key":"2020071713460878900_i1537-2073-16-1-55-b23","article-title":"Extavia [package insert]","year":"2011"},{"key":"2020071713460878900_i1537-2073-16-1-55-b24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/147323000503300306","article-title":"Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis","volume":"33","author":"Wroe","year":"2005","journal-title":"J Int Med Res"},{"key":"2020071713460878900_i1537-2073-16-1-55-b25","first-page":"15","article-title":"Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy","volume":"8","author":"Reess","year":"2002","journal-title":"Mult Scler"},{"key":"2020071713460878900_i1537-2073-16-1-55-b26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1017\/S031716710000038X","article-title":"Treatment with interferon beta-1b improves quality of life in multiple sclerosis","volume":"26","author":"Rice","year":"1999","journal-title":"Can J Neurol Sci"},{"key":"2020071713460878900_i1537-2073-16-1-55-b27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1212\/01.WNL.0000133206.44931.25","article-title":"Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial","volume":"63","author":"R\u00edo","year":"2004","journal-title":"Neurology"},{"key":"2020071713460878900_i1537-2073-16-1-55-b28","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1191\/1352458504ms1114oa","article-title":"A randomized open-label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis","volume":"10","author":"Leuschen","year":"2004","journal-title":"Mult Scler"},{"key":"2020071713460878900_i1537-2073-16-1-55-b29","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3111\/13696998.2010.527588","article-title":"Medication adherence with disease modifying treatments for multiple sclerosis among US employees","volume":"13","author":"Kleinman","year":"2010","journal-title":"J Med Econ"},{"key":"2020071713460878900_i1537-2073-16-1-55-b30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7224\/1537-2073-10.4.113","article-title":"Optimizing adherence to multiple sclerosis therapies","volume":"10","author":"Singer","year":"2008","journal-title":"Int J MS Care"},{"key":"2020071713460878900_i1537-2073-16-1-55-b31","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.clineuro.2010.12.013","article-title":"Injection of interferon-beta in the morning decreases flu-like syndrome in many patients with multiple sclerosis","volume":"113","author":"Nadjar","year":"2011","journal-title":"Clin Neurol Neurosurg"},{"key":"2020071713460878900_i1537-2073-16-1-55-b32","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0149-2918(04)90053-7","article-title":"A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis","volume":"26","author":"Phillips","year":"2004","journal-title":"Clin Ther"},{"issue":"24 suppl 3","key":"2020071713460878900_i1537-2073-16-1-55-b33","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1212\/WNL.0b013e31818f3da5","article-title":"Identification, causation, alleviation, and prevention of complications (ICAP): an approach to symptom and disability management in multiple sclerosis","volume":"71","author":"Cohen","year":"2008","journal-title":"Neurology"},{"key":"2020071713460878900_i1537-2073-16-1-55-b34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2119\/molmed.2011.00311","article-title":"Influence of dietary components on regulatory T cells","volume":"18","author":"Issazadeh-Navikas","year":"2012","journal-title":"Mol Med"},{"key":"2020071713460878900_i1537-2073-16-1-55-b35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00002018-200022020-00006","article-title":"Managing the adverse effects of interferon-beta therapy in multiple sclerosis","volume":"22","author":"Bayas","year":"2000","journal-title":"Drug Saf"},{"key":"2020071713460878900_i1537-2073-16-1-55-b36","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00415-009-0096-y","article-title":"Factors that influence adherence with disease-modifying therapy in MS","volume":"256","author":"Treadaway","year":"2009","journal-title":"J Neurol"},{"key":"2020071713460878900_i1537-2073-16-1-55-b37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01376517-200402000-00003","article-title":"Long-term treatment optimization in individuals with multiple sclerosis using disease-modifying therapies: a nursing approach","volume":"36","author":"Denis","year":"2004","journal-title":"J Neurosci Nurs"},{"key":"2020071713460878900_i1537-2073-16-1-55-b38","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/135245859600200502","article-title":"Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment","volume":"2","author":"Mohr","year":"1996","journal-title":"Mult Scler"}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/16\/1\/55\/2553444\/1537-2073_2013-006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/16\/1\/55\/2553444\/1537-2073_2013-006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:11:43Z","timestamp":1752786703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/nurses-perspective-on-approaches-to-limit-flu-like-symptoms-during-interferon-therapy-for-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2013-006","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3,1]]}}}